
Get exclusive money-saving offers and guides
Straight to your inbox
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Viking Therapeutics, Inc is a biotechnology business with stocks listed in the US. Viking Therapeutics shares (VKTX) are listed on the NASDAQ and all prices are listed in US Dollars. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | US$3.26 - US$10.09 |
---|---|
50-day moving average | US$7.4401 |
200-day moving average | US$6.6185 |
Target price | US$19.71 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | US$-0.353 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Gross profit TTM | US$0 |
---|---|
Return on assets TTM | -9.86% |
Return on equity TTM | -15.15% |
Profit margin | 0% |
Book value | 3.337 |
Market capitalisation | US$516 million |
TTM: trailing 12 months
There are currently 8.5 million Viking Therapeutics shares held short by investors – that's known as Viking Therapeutics's "short interest". This figure is 3.6% down from 8.8 million last month.
There are a few different ways that this level of interest in shorting Viking Therapeutics shares can be evaluated.
Viking Therapeutics's "short interest ratio" (SIR) is the quantity of Viking Therapeutics shares currently shorted divided by the average quantity of Viking Therapeutics shares traded daily (recently around 1.5 million). Viking Therapeutics's SIR currently stands at 5.49. In other words for every 100,000 Viking Therapeutics shares traded daily on the market, roughly 5490 shares are currently held short.
However Viking Therapeutics's short interest can also be evaluated against the total number of Viking Therapeutics shares, or, against the total number of tradable Viking Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Viking Therapeutics's short interest could be expressed as 0.12% of the outstanding shares (for every 100,000 Viking Therapeutics shares in existence, roughly 120 shares are currently held short) or 0.1499% of the tradable shares (for every 100,000 tradable Viking Therapeutics shares, roughly 150 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Viking Therapeutics.
Find out more about how you can short Viking Therapeutics stock.
We're not expecting Viking Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Viking Therapeutics's shares have ranged in value from as little as US$3.26 up to US$10.09. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Viking Therapeutics's is 1.7567. This would suggest that Viking Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta, which is in Phase 2b clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis. The company's lead drug candidate also includes VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery. It is also developing VK0612, an orally available Phase 2b-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta for X-linked adrenoleukodystrophy. Viking Therapeutics, Inc. was founded in 2012 and is headquartered in San Diego, California.
From the best sheets for summer to the most luxurious threads, these are the seven best bed sheets you can get in Australia right now.
Everything we know about the Bumble IPO, plus information on how to buy in.
Steps to owning and managing MicroStrategy shares.
Everything we know about the Kuaishou IPO, plus information on how to buy in.
Everything we know about the Coinbase IPO, plus information on how to buy in.
Everything we know about the Databricks IPO, plus information on how to buy in.
Steps to owning and managing Ligand Pharmaceuticals shares.
You can't access Robinhood in Australia, so here are five low-cost alternatives to trade US stocks.
Reddit has long been home to a huge retail investing community called WallStreetBets. Find out how to get the latest Reddit-tipped stocks here.
Steps to owning and managing Koss shares.